The first- national clinical trial of medical cannabis oil extracts for multiple cancer-related symptoms has re-opened and is recruiting patients and cancer survivors who continue to experience cancer-related symptoms. The study will evaluate three cannabis oils, using extracts already publicly available, on four cancer-related symptoms: nausea, pain, anxiety, and insomnia...READ MORE

Amgen announced new data from the DeLLphi300 clinical trial, a Phase 1 dose exploration and expansion study evaluating the safety and efficacy of investigational tarlatamab, a potential first-in-class half-life extended bispecific T-cell engager (HLE BiTE®) molecule targeting delta-like ligand 3, in small cell lung cancer. Updated data from the ongoing Phase 1 study were presented at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer in Vienna, Austria...READ MORE

Pfizer Inc. and Global Blood Therapeutics (GBT), Inc. announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). The acquisition complements and further enhances Pfizer’s more than 30-year heritage in rare hematology and reinforces the company’s commitment to SCD by...READ MORE

Pfizer Inc. and Valneva SE announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists, to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15. “With increasing global rates of Lyme disease, providing a new option for people to help protect themselves from the disease is more important than ever,” said Annaliesa Anderson, Ph.D., Senior Vice President and Head of Vaccine Research & Development at Pfizer...READ MORE

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of Nicole Lemerond to its Board of Directors, effective immediately. Nicole Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance. She has significant experience executing complex transactions, managing diligence processes, raising capital and structuring balance sheets...READ MORE

Are you looking to scale up your innovative digital health or medical technology company and gain a foothold in Asia? If so, the Canadian Trade Commissioner Service (TCS) invites you to apply for the Healthcare Technology – Canadian Technology Accelerator, a comprehensive virtual program designed to help your business foster strategic partnerships, tap into the Taiwanese healthcare industry, and expand to Taiwan and Asia at large...READ MORE

If you feel like you’re part of something bigger, it’s because you are. At Amgen, our shared mission—to serve patients—drives all that we do. It is key to our becoming one of the world’s leading biotechnology companies. We are global collaborators who achieve together—researching, manufacturing, and delivering ever-better products that reach over 10 million patients worldwide. It’s time for a career you can be proud of. Join us.

We now invite applications for a full-time tenure-track Assistant Professor position in Pharmacology. Applicants for this position must possess a PhD or equivalent doctoral qualification, with research expertise that broadens our current strengths in cancer pharmacology, cardiovascular pharmacology, diabetes, drug metabolism/pharmacokinetics, neuropharmacology, and pharmacogenomics or complements these strengths with a research focus in pharmacology.